<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781377</url>
  </required_header>
  <id_info>
    <org_study_id>1632/08 COET</org_study_id>
    <nct_id>NCT01781377</nct_id>
  </id_info>
  <brief_title>Prophylactic Subhypnotic Propofol for Nausea and Vomiting During for Cesarean Section Under Subarachnoid Anesthesia.</brief_title>
  <official_title>Randomized Controlled Trial of Prophylactic Subhypnotic Propofol vs Metoclopramide and in Combination Therapy for the Prevention of Nausea and Vomiting During Subarachnoid Anesthesia for Cesarean Section.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G. d'Annunzio University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>G. d'Annunzio University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative nausea and vomiting may occur in 50-80% of patients undergoing cesarean
      section.

      Metoclopramide is a well known Dopamine receptor antagonist that acts at the Chemoreceptor
      trigger zone and is used effectively for the prevention and treatment of nausea and vomiting.
      Propofol can antagonize Serotonin receptors in the area postremal and is associated to a
      reduced incidence of postoperative nausea and vomiting. Some studies have shown that propofol
      can prevent intraoperative nausea and vomiting during cesarean section.

      The control of risk factors and the pharmacological prophylaxis of nausea and vomiting
      reduces effectively their incidence.

      In this randomized, double blind, case-control study the efficacy of propofol alone,
      metoclopramide alone and in combination in controlling nausea and vomiting were compared. A
      risk factor control strategy was associated to each study group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NAUSEA AND VOMITING ASSOCIATED WITH CESAREAN SECTION</measure>
    <time_frame>FROM ANESTHESIA TO THE END OF SURGERY (AVERAGE 2 HOURS)</time_frame>
    <description>INCIDENCE OF NAUSEA AND VOMITING</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADVERSE EVENTS</measure>
    <time_frame>FROM ANESTHESIA TO THE END OF SURGERY (AVERAGE 2 HOURS)</time_frame>
    <description>HEADACHE, AGITATION, SEDATION.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>PREGNANCY</condition>
  <arm_group>
    <arm_group_label>PROPOFOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>METOCLOPRAMIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PROPOFOL &amp; METOCLOPRAMIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SALINE INFUSION</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PROPOFOL</intervention_name>
    <description>PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS</description>
    <arm_group_label>PROPOFOL</arm_group_label>
    <arm_group_label>PROPOFOL &amp; METOCLOPRAMIDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>METOCLOPRAMIDE</intervention_name>
    <description>METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS</description>
    <arm_group_label>METOCLOPRAMIDE</arm_group_label>
    <arm_group_label>PROPOFOL &amp; METOCLOPRAMIDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>SALINE INFUSION</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        CESAREAN SECTION WITHOUT MATERNAL OR FETAL SUFFERING

        American Society of Anesthesiologists score I-II

        36 TO 41 WEEK OF GESTATION

        BMI &lt; 35

        HEMOGLOBIN &gt; 10 mg/dl

        NO COMPLICATIONS (GESTATIONAL DIABETES, COLESTASIS)

        NO ACUTE OR CHRONIC GASTROINTESTINAL DISORDERS (GERD excluded)

        NO SMOKING OR DRUG ABUSE DURING PREGNANCY

        NO PREVIOUS MAJOR ABDOMINAL SURGERY

        NO PREVIOUS COMPLICATED PREGNANCIES

        FETAL WEIGHT &gt; 2.5 kg

        Exclusion Criteria:

        EMERGENCY CESAREAN SECTION WITH MATERNAL OR FETAL SUFFERING

        American Society of Anesthesiologists score III-IV-V

        &lt; 36 OR &gt; 41 WEEK OF GESTATION

        BMI &gt; 35

        HEMOGLOBIN &lt; 10 mg/dl

        COMPLICATIONS (GESTATIONAL DIABETES, COLESTASIS)

        ACUTE OR CHRONIC GASTROINTESTINAL DISORDERS

        SMOKING OR DRUG ABUSE DURING PREGNANCY

        PREVIOUS MAJOR ABDOMINAL SURGERY

        PREVIOUS COMPLICATED PREGNANCIES

        FETAL WEIGHT &lt; 2.5 kg
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZHIRAJR MOKINI, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera San Gerardo di Monza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FLAVIA PETRINI, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Chieti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MICHELE SCESI, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Chieti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. SS.ma Annunziata</name>
      <address>
        <city>Chieti</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2013</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera San Gerardo di Monza</investigator_affiliation>
    <investigator_full_name>Zhirajr Mokini</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>NAUSEA</keyword>
  <keyword>VOMITING</keyword>
  <keyword>CESAREAN SECTION</keyword>
  <keyword>PREVENTION</keyword>
  <keyword>PROPOFOL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

